Bone Morphogenetic Protein 13 Has Protumorigenic Effects on Hepatocellular Carcinoma Cells In Vitro.

Area of Science:

• Hepatology
• Oncology
• Molecular Biology

Background:

• Activated hepatic stellate cells (HSCs) are crucial in liver fibrosis and hepatocarcinogenesis.
• HSCs promote hepatocellular carcinoma (HCC) progression, but underlying mechanisms are not fully understood.
• Bone morphogenetic protein 13 (BMP13) is newly identified in HSCs within fibrotic liver tissue.

Purpose of the Study:

• To investigate the expression and function of BMP13 in hepatocellular carcinoma (HCC).
• To determine the cellular source and signaling pathways of BMP13 in HCC.
• To evaluate the therapeutic potential of targeting BMP13 in HCC.

Main Methods:

• Expression analysis of BMP13 in human HSCs and HCC cell lines.
• Immunofluorescence staining to confirm co-localization of BMP13 and alpha-smooth muscle actin (α-SMA) in HCC tissues.
• Stimulation of HCC cells with recombinant BMP13 and assessment of downstream signaling (SMAD, ERK) and gene expression (ID1, ID2, CDKN1A, CDKN2A).
• In vitro proliferation and clonogenicity assays.
• Inhibition studies using the ALK2/3 inhibitor dorsomorphin 1 (DMH1).

Main Results:

• High BMP13 expression was found in activated human HSCs, correlating with α-SMA, but not in HCC cell lines.
• BMP13 stimulation of HCC cells increased proliferation, colony formation, and expression of cell-cycle promoters ID1/ID2.
• BMP13 signaling involved SMAD and ERK phosphorylation and reduced expression of cell-cycle inhibitors CDKN1A/CDKN2A.
• The protumorigenic effects of BMP13 were blocked by DMH1, indicating action via ALK2/3 receptors.

Conclusions:

• Stroma-derived BMP13 acts as a novel tumor promoter in hepatocellular carcinoma (HCC).
• BMP13 signaling enhances HCC cell proliferation through specific molecular pathways.
• BMP13 represents a potential new therapeutic target for HCC treatment.